Related Experiment Video
Updated: Jun 19, 2026
06:51
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer
H H Nelson1, B C Christensen, S L Plaza
1Masonic Cancer Center, Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN 55455, USA. hhnelson@umn.edu
Lung Cancer (Amsterdam, Netherlands)
|October 27, 2009
Summary
The let-7 microRNA targets RAS genes in lung cancer. A KRAS polymorphism (LCS6) was investigated for its association with KRAS mutations and patient survival, but no significant links were found, limiting its clinical utility.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The let-7 microRNA family plays a crucial role in regulating gene expression within lung cancer.
- KRAS, a member of the RAS gene family, is a significant oncogene implicated in lung adenocarcinoma development and prognosis.
- A specific single nucleotide polymorphism (SNP) in the KRAS 3' UTR, known as LCS6, affects let-7 binding, leading to increased KRAS expression.
Purpose of the Study:
- To investigate the association between the KRAS LCS6 polymorphism and the presence of KRAS mutations in lung cancer.
- To determine if the KRAS LCS6 polymorphism is linked to patient survival outcomes in lung cancer.
Main Methods:
- Genotyping analysis was performed to identify the presence of the KRAS LCS6 polymorphism.
- Statistical methods were employed to assess the correlation between the LCS6 polymorphism and KRAS mutation status.
- Survival analysis was conducted to evaluate the relationship between the LCS6 polymorphism and patient prognosis.
Main Results:
- No statistically significant association was observed between the KRAS LCS6 polymorphism and the occurrence of KRAS mutations.
- The study found no significant correlation between the KRAS LCS6 polymorphism and lung cancer patient survival.
- These findings were unexpected given the known functional impact of the LCS6 polymorphism on let-7 binding and KRAS expression.
Conclusions:
- The KRAS LCS6 polymorphism does not appear to be a reliable biomarker for predicting KRAS mutation status in lung cancer.
- The LCS6 polymorphism shows limited clinical utility for non-small cell lung cancer (NSCLC) in terms of patient survival prediction.
- Further research may be needed to fully elucidate the role of this polymorphism in lung cancer pathogenesis or other clinical contexts.
Related Concept Videos
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
01:33Cancer-Critical Genes I: Proto-oncogenes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...